Taro earnings
This article was originally published in The Tan Sheet
Executive Summary
Hawthorne, N.Y.-based firm cites advertising expenses in support of ElixSure cough/cold and Kerasal moisturizer lines as a reason for an approximate 55% reduction in first-quarter net earnings to $5 mil. Overall sales declined approximately 7% to $84.1 mil., Taro reported April 26. The costs were incurred prior to the product lines' March divestment, the company maintains. Taro turned over North American marketing and distribution rights for the lines to Alterna in March (1"The Tan Sheet" March 7, 2005, p. 11)...
You may also be interested in...
Taro Readies Branded OTC Exodus With ElixSure, Kerasal Divestiture
Taro's divestiture of its ElixSure cough/cold medicine and Kerasal moisturizer brands in North America to Alterna signals the firm's exit from the branded OTC drug market
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.